376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Shanu Modi(Memorial Sloan Kettering Cancer Center), William Jacot(Institut de Recherche en Cancérologie de Montpellier), Hiroji Iwata(Aichi Cancer Center), Y.H. Park(Samsung Medical Center), M.J. Vidal Losada(Hospital Clínic de Barcelona), Wei Li(Jilin University), Junji Tsurutani(Showa University), Khalil Zaman, Naoto T. Ueno(University of Hawaiʻi at Mānoa), Aleix Prat(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Konstantinos Papazisis(Euromedica), H. S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Nadia Harbeck(Ludwig-Maximilians-Universität München), S-A. Im(Seoul National University Hospital), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Cecilia Orbegoso, Lotus Yung(Daiichi Sankyo (United States)), F-C. Cheng(Daiichi Sankyo (United States)), Yun Cheng(Daiichi Sankyo (United States)), David Cameron(Edinburgh Cancer Research)
Cited by 36Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis